Genitourinary Radiology: Page 15

Monrol to supply Telix with Lu-177 for renal cancer trial

By AuntMinnie.com staff writers

Eczacıbaşı-Monrol Nuclear Products will provide lutetium-177 (Lu-177) to Telix Pharmaceuticals Limited for a phase II clinical trial of its Starlite 2 renal cancer therapy medication TLX250.

May 10, 2022

MRI radiomics help predict prostate cancer metastases

By Kate Madden Yee

Radiomics features extracted from multiparametric MRI exams can help predict whether prostate cancer will metastasize, according to research presented at the International Society for Magnetic Resonance in Medicine meeting in London, U.K.

May 8, 2022

Radiomics, AI primed for bigger role in genitourinary applications

By Erik L. Ridley

Clinical use of radiomics and artificial intelligence (AI) in genitourinary applications has been limited to date, but that's likely to change in the future, according to a talk at the American Roentgen Ray Society meeting in New Orleans.

May 4, 2022

Fujitsu partners in Japan on AI for pancreatic cancer

By AuntMinnie.com staff writers

Fujitsu is partnering with a Japanese hospital on developing artificial intelligence (AI) technology for identifying pancreatic cancer on noncontrast CT exams.

April 24, 2022

Dialysis firm DaVita acquitted on labor collusion charges

By AuntMinnie.com staff writers

A federal jury in Colorado has acquitted kidney dialysis provider DaVita of conspiring with other firms -- including national radiology practice Radiology Partners -- of colluding to not hire each other's executives, according to an article in the Denver Post.

April 18, 2022

RSIP Vision launches new AI software for prostate MRI analysis

By AuntMinnie.com staff writers

Computer software and artificial intelligence (AI) company RSIP Vision has released an AI-based algorithm for prostate MRI analysis to support Prostate Imaging Reporting and Data System scoring.

April 10, 2022

Structural racism causes disparities in prostate MRI use

By Kate Madden Yee

Structural racism causes disparities in the use of MRI among Black and white men diagnosed with prostate cancer, with Black men less likely to get scans, according to research published March 3 in JAMA Oncology.

March 3, 2022

ECR: How can imaging screen for COVID damage to kidneys?

By Kate Madden Yee

With the COVID-19 pandemic now in at least a fourth wave, physicians have a better understanding of how the disease affects the body beyond the lungs -- including the kidneys, according to a session offered at the ECR 2022 Overture.

March 2, 2022

FDA clears Theragnostics kidney agent NephroScan

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has cleared for market the NephroScan technetium-99m (Tc-99m) radiodiagnostic imaging agent from radiopharmaceuticals firm Theragnostics.

February 22, 2022

MRI and PET match diagnosing prostate cancer

By Will Morton

MRI and PSMA-PET are equally effective diagnostic tools for detecting clinically significant tumors in patients with prostate cancer, according to a study published February 16 in the Journal of Medical Imaging and Radiation Oncology.

February 17, 2022

Shine and Telix ink Lu-177 supply deal

By AuntMinnie.com staff writers

Medical isotope company Shine Technologies and Telix Pharmaceuticals have signed an agreement covering the supply of lutetium-177 (Lu-177) to Telix for clinical development of potential new therapeutics to treat prostate and kidney cancer.

February 9, 2022

Ionetix, Precision Molecular ink supply deal

By AuntMinnie.com staff writers

Cyclotron technology developer Ionetix and imaging biomarker and theranostics firm Precision Molecular have signed a supply deal for the therapeutic isotope astatine-211.

January 27, 2022

Previous Page

Page 15 of 95

Next Page